Asset profile
LP-98
Peptide
Evidence outlook · results not reported
NCT06560489 · Hiv
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
NCT06560489: The study randomly assigned 40 participants to four blinded LP-98 dose groups, but it did not include a placebo or active-control arm. Its primary outcomes were laboratory, vital-sign, and electrocardiographic measures rather than hard clinical outcomes, and the primary results are not yet available.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 3 direct rivals (same mechanism and indication), 0 same-class, 57 same-indication; 46 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| LP-98: this drug | Phase 1/2 | Peptide | HIV gp41 | ||
| Albuvirtide (Aikening) | Phase 3 | Peptide | HIV gp41 | ||
| Lipovirtide | Phase 2 | Peptide | HIV gp41 | ||
| CPT31 | Phase 1 | Peptide | HIV gp41 | ||
| Bictegravir (Biktarvy) | Approved | Small molecule | HIV integrase | ||
| Cabotegravir (Vocabria / Cabenuva / Apretude) | Approved | Small molecule | HIV integrase | ||
| Crofelemer (Mytesi) | Approved | Small molecule | Chloride channel (intestinal epithelium) | ||
| Darunavir (Prezista) | Approved | Small molecule | HIV protease | ||
| Dolutegravir (Tivicay / Triumeq / Dovato / Juluca (component)) | Approved | Small molecule | HIV integrase | ||
| Doravirine (Pifeltro) | Approved | Small molecule | HIV reverse transcriptase | ||
| Elsulfavirine (Elpida) | Approved | Small molecule | HIV reverse transcriptase | ||
| Elvitegravir (Stribild / Genvoya (component)) | Approved | Small molecule | HIV integrase | ||
| Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada) | Approved | Small molecule | HIV reverse transcriptase | ||
| Etravirine (Intelence) | Approved | Small molecule | HIV reverse transcriptase | ||
| Fosamprenavir (Lexiva / Telzir) | Approved | Small molecule | HIV protease | ||
| Fostemsavir (Rukobia) | Approved | Small molecule | HIV gp120 |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.